A phase II study of alternating paclitaxel and carboplatin in patients with advanced ovarian cancer

被引：0
|
作者：
Adams, M
Mort, D
Coleman, R
Wiliams, L
Evans, A
Thompson, M
机构：
[1] VELINDRE HOSP NHS TRUST,CARDIFF,S GLAM,WALES
[2] WESTON PK HOSP TRUST,SHEFFIELD,S YORKSHIRE,ENGLAND
[3] BRISTOL MYERS SQUIBB,PHARMACEUT RES INST,HOUNSLOW,ENGLAND
来源：
EUROPEAN JOURNAL OF CANCER | 1995年 / 31A卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：496 / 496
页数：1
相关论文
共 50 条
  • [21] Phase I study of metformin in combination with carboplatin/paclitaxel chemotherapy in patients with advanced epithelial ovarian cancer
    Broekman, K. Esther
    Hof, Marieke A. J.
    Touw, Daan J.
    Gietema, Jourik A.
    Nijman, Hans W.
    Lefrandt, Joop D.
    Reyners, An K. L.
    Jalving, Mathilde
    INVESTIGATIONAL NEW DRUGS, 2020, 38 (05) : 1454 - 1462
  • [22] Carboplatin and paclitaxel in patients with advanced ovarian cancer: A dose-finding study
    Huinink, WT
    Veenhof, C
    Huizing, M
    Rodenhuis, S
    Helmerhorst, T
    Dubbelman, R
    Dalesio, O
    Beijnen, J
    Winograd, B
    SEMINARS IN ONCOLOGY, 1997, 24 (01) : S31 - S33
  • [23] Phase II study of carboplatin and paclitaxel in patients with advanced upper gastrointestinal cancers
    Philip, PA
    Gadgeel, S
    Hussain, M
    Zalupski, MM
    Shields, AF
    SEMINARS IN ONCOLOGY, 1999, 26 (01) : 141 - 141
  • [24] Combination paclitaxel plus Carboplatin versus paclitaxel with alternating Carboplatin and cisplatin as first line treatment for advanced ovarian cancer (AOC)
    Aravantinos, G
    Fountzilas, G
    Kosmides, P
    Stathopoulos, GP
    Pavlidis, N
    Dimopoulos, MA
    Bafaloukos, D
    Papakostas, P
    Papadimitriou, C
    Nikolaides, G
    Skarlos, DV
    ANNALS OF ONCOLOGY, 1998, 9 : 66 - 66
  • [25] Phase I study of carboplatin, doxorubicin and weekly paclitaxel in patients with advanced ovarian carcinoma
    Hess, V
    Verrill, MW
    Bomphray, CC
    Vaughan, MM
    Allen, M
    Gore, ME
    ANNALS OF ONCOLOGY, 2003, 14 (04) : 638 - 642
  • [26] A phase II study of frontline paclitaxel/carboplatin/bevacizumab, paclitaxel/carboplatin/temsirolimus, or ixabepilone/carboplatin/bevacizumab in advanced/recurrent endometrial cancer
    Aghajanian, Carol
    Filiaci, Virginia
    Dizon, Don S.
    Carlson, Jay W.
    Powell, Matthew A.
    Secord, Angeles Alvarez
    Tewari, Krishnansu S.
    Bender, David P.
    O'Malley, David M.
    Stuckey, Ashley
    Gao, Jianjiong
    Dao, Fanny
    Soslow, Robert A.
    Lankes, Heather A.
    Moore, Kathleen
    Levine, Douglas A.
    GYNECOLOGIC ONCOLOGY, 2018, 150 (02) : 274 - 281
  • [27] Phase II study of DMXAA combined with carboplatin and paclitaxel in recurrent ovarian cancer.
    Gabra, H.
    JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 263S - 263S
  • [28] Phase II study of weekly paclitaxel carboplatin in the treatment of progressive ovarian cancer.
    Van der Burg, ME
    Vergote, I
    Burger, CW
    van der Gaast, A
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 463S - 463S
  • [29] Phase II study of carboplatin followed by sequential gemcitabine and paclitaxel as first-line treatment for advanced ovarian cancer
    Friedlander, M.
    Buck, M.
    Wyld, D.
    Findlay, M.
    Fitzharris, B.
    De Souza, P.
    Davies, T.
    Kalimi, G.
    Allan, S.
    Perez, D.
    Harnett, P.
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2007, 17 (02) : 350 - 358
  • [30] Phase II study of neoadjuvant IGFBP-2 vaccination with neoadjuvant carboplatin and paclitaxel in advanced ovarian cancer.
    Gwin, William Rayford
    Childs, Jennifer
    Higgins, Doreen
    Shakalia, Hania
    Ben Liao, John
    Disis, Mary L.
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
12345